Expertise in
3
conditions

Akira Maeyama

Fukuoka, JP 
Expertise in
3
conditions
Fukuoka, JP 

Overview

Akira Maeyama practices practicing medicine in Fukuoka, Japan.

Maeyama is highly rated in 3 conditions, according to our data. Their clinical expertise encompasses Arthritis, Osteoarthritis, Hypermobile Joints, Osteotomy, and Knee Replacement.

They are actively involved in clinical research, co-authoring 58 peer reviewed articles and participating in 2 clinical trials.

Locations

Fukuoka, Japan
Other Locations
Nanakuma, 8140180, Japan
Japan
Tokyo, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
Enrollment Status: Terminated
Publish Date: February 07, 2024
Intervention Type: Drug, Biological
Study Drugs: Otilimab, csDMARD
Study Phase: Phase 3
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
Enrollment Status: Terminated
Publish Date: November 30, 2023
Intervention Type: Drug, Biological
Study Drugs: Otilimab, Tofacitinib, csDMARDs
Study Phase: Phase 3
View 1 Less Clinical Trial

58 Total Publications

Paradigm Shifts in Regenerative Medicine for Bone and Joint Surgery: From Mechanical Repair to Intelligent Biological Restoration.
Paradigm Shifts in Regenerative Medicine for Bone and Joint Surgery: From Mechanical Repair to Intelligent Biological Restoration.
Journal: Ortopedia, traumatologia, rehabilitacja
Published: March 29, 2026

Frequently Asked Questions about Akira Maeyama

Is Akira Maeyama a top-rated expert for Osteotomy?

MediFind is an objective health platform that identifies experts based on real-world data. Akira Maeyama is classified as an Distinguished expert for Osteotomy, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Akira Maeyama participate in research or clinical trials?

Yes. Akira Maeyama has published 58 articles and abstracts on conditions like Osteotomy. You can view a list of Akira Maeyama's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Maeyama's expertise for a condition
ConditionClose
    View All 13 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile